Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone therapy for growth impairment in children with chronic kidney disease
ChiCTR2500099135Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of somatropin in faltering growth (FTT) and chronic kidney disease (CKD), sponsored by Tongji Hospital. Primary endpoint: Change from baseline in height standard deviation score. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
somatropin
03
Conditions
faltering growth (FTT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500099135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099135.